Neuregulin-1 (NRG-1) is expressed in vascular endothelial cells, and its receptors are localized to the underlying smooth muscle cells. However, the role of NRG-1 in vascular function and injury is largely unknown. First, the expression of NRG-1 and its receptors (erbB receptors) was analyzed after balloon injury to the rat carotid artery. NRG-1 and erbB expression levels were low in uninjured vessels; however, NRG-1 and erbB4 were upregulated following injury. We then examined the effect of NRG-1 on neointimal formation following balloon injury. NRG-1 was administered by tail-vein injection prior to injury and every 2 days following injury. Two weeks after injury, NRG-1-treated animals demonstrated a 50% reduction in lesion size compared with controls receiving the vehicle. To examine possible mechanisms for NRG-1 action, we examined its effects on vascular smooth muscle cell (VSMC) function. Rat VSMC cultures were pretreated with NRG-1 for 24 h and then stimulated with platelet-derived growth factor. NRG-1 significantly decreased platelet-derived growth factor-stimulated VSMC proliferation and migration. These findings suggest that NRG-1 may be a novel therapeutic candidate for the treatment of restenosis and atherosclerosis.

Keywords:
Angioplasty, erbB receptor, Vascular injury, Vascular smooth muscle cells, Restenosis, Atherosclerosis
1.
Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
2.
Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–809.
3.
Raines EW, Ross R: Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993;69:S30–S37.
4.
Ross R, Glomset JA: Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332–1339.
5.
Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004;15:237–254.
6.
Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129–1132.
7.
Fukuda N, Furuya R, Kishioka H, Suzuki R, Matsuda H, Tahira Y, Takagi H, Ikeda Y, Saito S, Matsumoto K, Kanmatsuse K: Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells. J Cardiovasc Pharmacol 2003;42:224–231.
8.
Buonanno A, Fischbach GD: Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 2001;11:287–296.
9.
Fischbach GD, Rosen KM: ARIA: a neuromuscular junction neuregulin. Annu Rev Neurosci 1997;20:429–458.
10.
Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD: ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 1993;72:801–815.
11.
Talmage DA, Role LW: Multiple personalities of neuregulin gene family members. J Comp Neurol 2004;472:134–139.
12.
Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE, Birchmeier C: Isoform-specific expression and function of neuregulin. Development 1997;124:3575–3586.
13.
Panutsopulos D, Arvanitis DL, Tsatsanis C, Papalambros E, Sigala F, Spandidos DA: Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res 2005;42:463–474.
14.
Corfas G, Rosen KM, Aratake H, Krauss R, Fischbach GD: Differential expression of ARIA isoforms in the rat brain. Neuron 1995;14:103–115.
15.
Krymskaya VP, Hoffman R, Eszterhas A, Kane S, Ciocca V, Panettieri RA Jr: EGF activates ErbB-2 and stimulates phosphatidylinositol 3-kinase in human airway smooth muscle cells. Am J Physiol 1999;276:L246–L255.
16.
Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K, Elenius K: Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 2003;17:1609–1621.
17.
Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R: Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-β1-mediated angiogenesis. J Biol Chem 2000;275:39451–39457.
18.
Kumar R, Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol 2001;28:27–32.
19.
Russell KS, Stern DF, Polverini PJ, Bender JR: Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999;277:H2205–H2211.
20.
Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460–3469.
21.
Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H: Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 2003;23:795–801.
22.
Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM: Stress-activated protein kinases in cardiovascular disease. Circ Res 1996;78:947–953.
23.
Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE: Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997;29:334–339.
24.
Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003;284:14–30.
25.
Shin HS, Lee HJ, Nishida M, Lee MS, Tamura R, Yamashita S, Matsuzawa Y, Lee IK, Koh GY: Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res 2003;93:302–310.
26.
Yamanaka Y, Hayashi K, Komurasaki T, Morimoto S, Ogihara T, Sobue K: EGF family ligand-dependent phenotypic modulation of smooth muscle cells through EGF receptor. Biochem Biophys Res Commun 2001;281:373–377.
27.
Ferrer I, Planas AM: Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol 2003;62:329–339.
28.
Guegan C, Sola B: Early and sequential recruitment of apoptotic effectors after focal permanent ischemia in mice. Brain Res 2000;856:93–100.
29.
Matsushima K, Schmidt-Kastner R, Hogan MJ, Hakim AM: Cortical spreading depression activates trophic factor expression in neurons and astrocytes and protects against subsequent focal brain ischemia. Brain Res 1998;807:47–60.
30.
Guegan C, Ceballos-Picot I, Nicole A, Kato H, Onteniente B, Sola B: Recruitment of several neuroprotective pathways after permanent focal ischemia in mice. Exp Neurol 1998;154:371–380.
31.
Xu Z, Ford BD: Upregulation of erbB receptors in rat brain after middle cerebral arterial occlusion. Neurosci Lett 2005;375:181–186.
32.
Xu Z, Jiang J, Ford G, Ford BD: Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun 2004;322:440–446.
33.
Parker MW, Chen Y, Hallenbeck JM, Ford BD: Neuregulin expression after focal stroke in the rat. Neurosci Lett 2002;334:169–172.
34.
Erlich S, Shohami E, Pinkas-Kramarski R: Closed head injury induces up-regulation of ErbB-4 receptor at the site of injury. Mol Cell Neurosci 2000;16:597–608.
35.
Tokita Y, Keino H, Matsui F, Aono S, Ishiguro H, Higashiyama S, Oohira A: Regulation of neuregulin expression in the injured rat brain and cultured astrocytes. J Neurosci 2001;21:1257–1264.
36.
Lindholm T, Cullheim S, Deckner M, Carlstedt T, Risling M: Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system. Exp Brain Res 2002;142:81–90.
37.
Shyu WC, Lin SZ, Chiang MF, Yang HI, Thajeb P, Li H: Neuregulin-1 reduces ischemia-induced brain damage in rats. Neurobiol Aging 2004;25:935–944.
38.
Xu Z, Ford GD, Croslan DR, Jiang J, Gates A, Allen R, Ford BD: Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis 2005;19:461–470.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.